コンテンツにジャンプ
研究所ロゴ

トップページ > 研究組織一覧 > 分野・独立ユニットグループ > 新領域創成プロジェクトグループ > 分子薬理研究分野 > 論文業績

論文業績

更新日 : 2021年8月10日

  1. Taguchi K, Hayashi Y, Ohuchi M, Yamada H, Yagishita S, Enoki Y, Matsumoto K, Hamada A. Augmented clearance of nivolumab is associated with renal functions in chronic renal disease model rats. Drug Metab Dispos. 2021 Aug 4:DMD-AR-2021-000520. doi: 10.1124/dmd.121.000520.
  2. Yazaki S, Yoshida T, Kojima Y, Yagishita S, Nakahama H, Okinaka K, Matsushita H, Shiotsuka M, Kobayashi O, Iwata S, Narita Y, Ohba A, Takahashi M, Iwasa S, Kobayashi K, Ohe Y, Yoshida T, Hamada A, Doi T, Yamamoto N. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan. JAMA Oncol. 2021 May 28. doi: 10.1001/jamaoncol.2021.2159. Epub ahead of print. PMID: 34047762.
  3. Suzuki M, Yagishita S, Sugihara K, Ogitani Y, Nishikawa T, Ohuchi M, Teishikata T, Jikoh T, Yatabe Y, Yonemori K, Tamura K, Hasegawa K, Hamada A. Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Clin Cancer Res. 2021 May 12. doi: 10.1158/1078-0432.CCR-21-0397. Epub ahead of print. PMID: 33980613.
  4. Hayashi Y, Ohuchi M, Ryu S, Yagishita S, Hamada A. A procedure for method development and protein binding ratio as the indicator of sensitivity with anticancer agents on MALDI mass spectrometry imaging. Drug Metab Pharmacokinet. 2021 Jun;38:100385. doi: 10.1016/j.dmpk.2021.100385. Epub 2021 Jan 30. PMID: 33878680.
  5. Nitani C, Hara J, Kawamoto H, Taguchi T, Kimura T, Yoshimura K, Hamada A, Kitano S, Hattori N, Ushijima T, Ono H, Nakamoto M, Higuchi T, Sato A. Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors. Cancer Chemother Pharmacol. 2021 Jul;88(1):99-107. doi: 10.1007/s00280-021-04271-9. Epub 2021 Apr 7. PMID: 33829292.
  6. Matsuda K, Kobayakawa T, Kariya R, Tsuchiya K, Ryu S, Tsuji K, Ishii T, Gatanaga H, Yoshimura K, Okada S, Hamada A, Mitsuya H, Tamamura H, Maeda K. A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators. Front Microbiol. 2021 Mar 17;12:636276. doi: 10.3389/fmicb.2021.636276. PMID: 33815322; PMCID: PMC8010149.
  7. Yagishita S, Kato K, Takahashi M, Imai T, Yatabe Y, Kuwata T, Suzuki M, Ochiai A, Ohtsu A, Shimada K, Nishida T, Hamada A, Mano H. Characterization of the large-scale Japanese patient-derived xenograft (J-PDX) library. Cancer Sci. 2021 Mar 23. doi: 10.1111/cas.14899. Epub ahead of print. PMID: 33759313.
  8. Noda K, Matsuda K, Yagishita S, Maeda K, Akiyama Y, Terada-Hirashima J, Matsushita H, Iwata S, Yamashita K, Atarashi Y, Watanabe S, Ide N, Yoshida T, Ohmagari N, Mitsuya H, Hamada A. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci Rep. 2021 Mar 4;11(1):5198. doi: 10.1038/s41598-021-84387-3. PMID: 33664294; PMCID: PMC7933429.
  9. Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma. Clin Lung Cancer. 2021 Feb 8:S1525-7304(21)00026-7. doi: 10.1016/j.cllc.2021.02.003. Epub ahead of print. PMID: 33722498.
  10. Ohuchi M, Yagishita S, Taguchi K, Goto Y, Fukahori M, Enoki Y, Shimada T, Yamaguchi M, Matsumoto K, Hamada A. Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jan 1;1162:122489. doi: 10.1016/j.jchromb.2020.122489. Epub 2020 Dec 8. PMID:33385769.
  11. Hirata T, Ozaki S, Tabata M, Iwamoto T, Hinotsu S, Hamada A, Motoki T, Nogami T, Shien T, Taira N, Matsuoka J, Doihara H. A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer. Intern Med. 2020 Nov 16. doi: 10.2169/internalmedicine.5089-20.
  12. Otani S, Sasaki J, Nakahara Y, Fukui T, Igawa S, Naoki K, Bessho A, Hosokawa S, Fukamatsu N, Nakamura Y, Kasai T, Sugiyama T, Tokito T, Seki N, Hamada A, Okamoto H, Masuda N. Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320). Invest New Drugs. 2020 Nov 7.
  13. Ryu S, Ohuchi M, Yagishita S, Shimoi T, Yonemori K, Tamura K, Fujiwara Y, Hamada A. Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging. Sci Rep. 2020 Sep 23;10(1):15535.
  14. Ichikawa A, Fujita Y, Hosaka Y, Kadota T, Ito A, Yagishita S, Watanabe N, Fujimoto S, Kawamoto H, Saito N, Yoshida M, Hashimoto M, Minagawa S, Hara H, Motoi N, Yamamoto Y, Ochiya T, Araya J, Kuwano K. Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer. Cancer Sci. 2020 Nov;111(11):4154-4165. doi: 10.1111/cas.14629. Epub 2020 Sep 7. PMID: 32860290; PMCID: PMC7648026.
  15. Nosaki K, Yamanaka T, Hamada A, Shiraishi Y, Harada T, Himeji D, Kitazaki T, Ebi N, Shimose T, Seto T, Takenoyama M, Sugio K. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). Oncologist. 2020 Jul 12.
  16. Tsumura R, Koga Y, Hamada A, Kuwata T, Sasaki H, Doi T, Aikawa K, Ohashi A, Katano I, Ikarashi Y, Ito M, Ochiai A. The report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan. Cancer Sci. 2020 Jul 8.
  17. Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. JAMA Oncol. 2020 May 14:e201250. doi: 10.1001/jamaoncol.2020.1250.
  18. Shinno Y, Goto Y, Ohuchi M, Hamada A, Nokihara H, Fujiwara Y, Ohe Y. The long half-life of programmed cell death protein 1 inhibitors may increase the frequency of immune-related adverse events after subsequent EGFR tyrosine kinase inhibitor therapy. JTO Clinical and Research Reports. 2020 Feb 11;1(1):1-6.
  19. Osawa T, Shimamura T, Saito K, Hasegawa Y, Ishii N, Nishida M, Ando R, Kondo A, Anwar M, Tsuchida R, Hino S, Sakamoto A, Igarashi K, Saitoh K, Kato K, Endo K, Yamano S, Kanki Y, Matsumura Y, Minami T, Tanaka T, Anai M, Wada Y, Wanibuchi H, Hayashi M, Hamada A, Yoshida M, Yachida S, Nakao M, Sakai J, Aburatani H, Shibuya M, Hanada K, Miyano S, Soga T, Kodama T. Phosphoethanolamine Accumulation Protects Cancer Cells under Glutamine Starvation through Downregulation of PCYT2. Cell Rep. 2019 Oct 1;29(1):89-103.e7.
  20. Yagishita S, Hamada A. Monoclonal antibody pharmacogenomics in cancer treatment. J Cancer Metastasis Treat 2019;5:75.
  21. Endo-Tsukude C, Kato M, Kaneko A, Iida S, Kuramoto S, Ishigai M, Hamada A. Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes. Drug Metab Pharmacokinet. 2019 Oct;34(5):325-333.
  22. Iwamoto N, Takanashi M, Shimada T, Sasaki J, Hamada A. Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay. AAPS J. 2019 Aug 20;21(6):101.
  23. Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K. Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. Transl Oncol. 2019 Aug 2;12(10):1386-1394.
  24. Nishidate M, Hayashi M, Aikawa H, Tanaka K, Nakada N, Miura S, Ryu S, Higashi T, Igarashi Y, Fujiwara Y, Hamada A. Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. Drug Metab Pharmacokinet. 2019 Aug;34(4):209-216.
  25. Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci. 2019 Jul;110(7):2247-2257.
  26. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. Eur J Cancer. 2019 Mar;109:84-91.
  27. Mizugaki H, Hamada A, Shibata T, Hosoda F, Nakamura H, Okuma Y, Shukuya T, Umemura S, Horiike A, Fukui T, Kogure Y, Daga H, Urata Y, Yamada K, Saeki S, Fujisaka Y, Nakamura Y, Sato M, Yoshida T, Hotta T, Oizumi S, Fujiwara Y, Ohe Y, Fujiwara Y. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing, Lung Cancer. 2019 Feb;128:20-25.
  28. Okimoto T, Tsubata Y, Hotta T, Hamaguchi M, Nakao M, Hamaguchi SI, Hamada A, Isobe T. A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis. Intern Med. 2019 Mar 1;58(5):703-705.
  29. Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, Sudo K, Shimomura A, NoguchI E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K. PIK3CA-mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer Sci. 2018 Aug;109(8):2558-2566.
  30. Nishimura M,  Hayashi M, Mizutani Y, Takenaka K,  Imamura Y, Chayahara N, Toyoda M, Kiyota N, Mukohara T, Aikawa H, Fujiwara Y, Hamada A, Minami H. Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. Oncotarget. 2018; 9時18分540-18547.
  31. Endo-Tsukude C, Sasaki JI, Saeki S, Iwamoto N, Inaba M, Ushijima S, Kishi H, Fujii S, Semba H, Kashiwabara K, Tsubata Y, Hayashi M, Kai Y, Saito H, Isobe T, Kohrogi H, Hamada A. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. Biol Pharm Bull. 2018;41(1):47-56.
  32. Nishidate M, Yamamoto K, Masuda C, Aikawa H, Hayashi M, Kawanishi T, Hamada A. MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells. Sci Rep.2017 Dec 1;7(1):16763.
  33. Iwamoto N, Hamada A, Shimada T. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. Anal Biochem. 2017 Nov 9;540-541:30-37.
  34. Ryu S, Hayashi M, Aikawa H, Okamoto I, Fujiwara Y, Hamada A. Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study. Br J Pharmacol. 2018 Jan;175(1):29-37.
  35. Tsubata Y, Hayashi M, Tanino R, Aikawa H, Ohuchi M, Tamura K, Fujiwara Y, Isobe T, Hamada A. Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. Sci Rep. 2017 Oct 3;7(1):12622.
  36. Ogata-Aoki H, Higashi-Kuwata N, Hattori SI, Hayashi H, Danish M, Aoki M, Shiotsu C, Hashiguchi Y, Hamada A, Kobayashi H, Ihn H, Okada S, Mitsuya H. Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1(JR-FL) in the setting of post-exposure prophylaxis in NOD/SCID/Jak3(-/-) mice transplanted with human PBMCs. Antiviral Res. 2017 Sep 8. pii: S0166-3542(17)30265-6.
  37. Tsuchiya K, Hayashida T, Hamada A, Oki S, Oka S, Gatanaga H. High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genomics. 2017 Aug 29.
  38. Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K. Visualization of HER2-specific breast cancer intratumoral heterogeneity using (64) Cu-DOTA-trastuzumab PET. Eur J Nucl Med Mol Imaging. 2017 Aug 3.
  39. Tsuchiya K, Ohuchi M, Yamane N, Aikawa H, Gatanaga H, Oka S, Hamada A. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir, and elvitegravir concentrations in human plasma and cerebrospinal fluid samples. Biomed Chromatogr. 2017 Jul 31.
  40. Iwamoto N, Shimomura A, Tamura K, Hamada A, Shimada T. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. J Pharm Biomed Anal. 2017 Jun 19;145:33-39.
  41. Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol.  2017 Jun;79(6):1179-1186.
  42. Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I. Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401). J Thorac Oncol. 2017 Jul;12(7):1161-1166.
  43. Tamura T, Hirata T, Tabata M, Hinotsu S, Hamada A, Motoki T, Iwamoto T, Mizoo T, Nogami T, Shien T, Taira N, Matsuoka J, Doihara H. A Phase I Trial of 100 mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer. Acta Med Okayama. 70(5):425-427(2016).
  44. Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, Shinohara M, Hamada A, Jono H, Yuba E, Kono K, Yoshida K, Tsunoda T, Nakayama H, Nishimura Y. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. Oncoimmunology. 4;5(6):e1123368(2016).
  45. Fujiwara Y, Hamada A, Mizugaki H, Aikawa H, Hata T, Horinouchi H, Kanda S, Goto Y, Itahashi K, Nokihara H, Yamamoto N, Ohe Y. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism, Cancer Sci, 17時11分17-23(2016).
  46. Iwamoto N, Shimada T, Terakado H, Hamada A. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis. J Chromatogr B Analyt Technol Biomed Life Sci. 27;1023-1024:9-16 (2016).
  47. Yamagishi M, Tsuta K, Shimoi T, Tanabe Y, Hirai M, Kohno T, Shiraishi K, Nakaoku T, Sunami K, Shimada Y, Tamura K, Hamada A.  Automated and rapid system for detection of ALK rearrangement genes in non-small cell lung cancer based on a Quenching Probe method,  Biomed Res Clin Prac, 1時36分-41(2016).
  48. Iwamoto N, Takanashi M, Hamada A, Shimada T. Validated LC/MS bioanalysis of Rituximab CDR peptides using nano-surface and molecular-orientation limited (nSMOL) proteolysis. Biol Pharm Bull. 39:1187-94(2016).
  49. Tsuchiya K, Hayashida T, Hamada A, Oka S, Gatanaga H. Brief Report: High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants. J Acquir Immune Defic Syndr. 72(1):11-4(2016).
  50. Aikawa H, Hayashi M, Ryu S, Yamashita M, Ohtsuka N, Nishidate M, Fujiwara Y, Hamada A.  Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging, Sci Rep, 30;6時23分749(2016).
  51. Iwamoto N, Takanashi M, Umino Y, Aoki C, Hamada A, Shimada T. Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab. Bioanalysis. 8時10分09-1020(2016).
  52. Iwamoto N, Umino Y, Aoki C, Yamane N, Hamada A, Shimada T. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis. Drug Metab Pharmacokinet. 31(1):46-50(2016).
  53. Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, Tamura K, Hamada A.  A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells, Sci Rep. 27;6時19分772 (2016).
  54. Kurihara H, Shimizu C, Miyakita Y, Yoshida M, Hamada A, Kanayama Y, Yonemori K, Hashimoto J, Tani H, Kodaira M, Yunokawa M, Yamamoto H, Watanabe Y, Fujiwara, Y, Tamura K. Molecular imaging using PET for breast cancer. Breast Cancer. 23(1):24-32(2016).
  55. Hayashi M, Yamamoto Y, Sueta A, Tomiguchi M, Yamamoto-Ibusuki M, Kawasoe T, Hamada A, Iwase H. Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer Medicine (Baltimore). 2015 Dec;94(50):e2290.
  56. Fujiwara Y,  Kobayashi S, Nagano H, Kanai M, Hatano E, Toyoda M, Ajiki T, Takashima Y, Hamada A, Minami H, Ioka T. Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101), PLOS ONE, 3;10(12):e0143072(2015).
  57. Otani S, Hamada A, Sasaki J, Wada M, Yamamoto M, Ryuge S, Takakura A, Fukui T, Yokoba M, Mitsufuji H, Toyooka T, Maki S, Kimura M, Hayashi N, Ishihara M, Kasajima M, Hiyoshi Y, Nagashima Y, Katono K, Igawa S, Kubota M, Katagiri M, Saito H, Masuda N. Phase I and Pharmacokinetic Study of Erlotinib Administered in Combination With Amrubicin in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer. Am J Clin Oncol, 38:405-10(2015).
  58. Iwamoto N, Umino Y, Yamane N, Hamada A, Shimada T. Development of the validated LCMS bioanalysis of Trastuzumab in human plasma using selective detection method for complementarity-determining regions of monoclonal antibody: nano-surface and molecular-orientation limited (nSMOL) proteolysis, Analytical Methods, 7: 9177-9183(2015).
  59. Katsuya Y, Fujiwara Y, Sunami K, Utsumi H, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Takashima Y, Osawa S, Ohe Y, Tamura T, Hamada A. Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer. Cancer Chemother Pharmacol, 76:125-32(2015).
  60. Oguri T, Shimokata T, Ito I, Yasuda Y, Sassa N, Nishiyama M, Hamada A, Hasegawa Y, Ando Y. Extension of the Calvert formula to patients with severe renal insufficiency, Cancer Chemo Phamacol, 76:53-9(2015).
  61. Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada Y, Kodaira M, Yunokawa M, Yamamoto H, Shimizu C, Takahashi K, Watanabe Y, Fujiwara Y, Tamura K. 64Cu-DOTA-trastuzumab PET imaging and HER2-specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Research, 5時8分(2015).
  62. Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kenta Kawahara K, Nakagawa Y, Yoshida R, Hirosue A, Ogi H, Hiraki A, Jono H, Hamada A, Yoshida K, Nishimura Y, Nakamura Y, Shinohara M. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS, Clin Cancer Res, 21時31分2-21(2015).
  63. Sakata S, Sasaki S, Saeki S, Hamada A, Kishi H, Nakamura K, Notsute D, Sato R, Saruwatari K, Iriki T, Tanaka H, Akaike K, Fujii S, Hirosako S, Kohrogi H. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced non-squamous, non-small-cell lung cancer: Kumamoto Thoracic Oncology Study Group Trial 1002, Oncology, 88:201-207(2015).
  64. Yagishita S, Hamada A. Clinical pharmacology of EGFR/Met inhibitors in non-small cell lung cancer, Current Drug Target, 21時31分2-321(2014).
  65. Yamakawa Y, Hamada A, Uchida T, Sato D, Yuki M, Hayashi M, Kawaguchi T, Saito H. Distinct Interaction of Nilotinib and Imatinib with P-Glycoprotein in Intracellular Accumulation and Cytotoxicity in CML Cell Line K562 Cells. Biol Pharm Bull. 37(8):1330-5 (2014).
  66. Hirakawa A, Yonemori K, Kuwatsuka Y, Kodaira M, Yamamoto H, Yunokawa M, Hamada A, Shimizu C, Tamura K, Gemma A, Fujiwara Y. A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease using Spontaneous Reporting Data in Japan. Curr Drug Saf. 9時22分0-226(2014).
  67. Tuchiya K, Hayashida T, Hamada A, Kato S, Oka S, Gatanaga H. Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants, J Acquir Immune Defic Syndr, 166:484-486(2014).
  68. Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H,Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, NakamuraY, Shinohara M, Nishimura Y. LY6K-specific CD4+ T-cell immunity in patients with malignant tumor: Identification of LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes. OncoImmunology, 3:e28100, 2014.
  69. Tomita Y, Yuno A, Tsukamoto H, Senju S, Yoshimura S, Osawa R, KurodaY, Hirayama M, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Identification of CDCA1 long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients. Int. J. Cancer 134: 352-366, 2014.
  70. Iwamoto N, Umino Y, Aoki C, Aoki Y, Sato T, Hamada A, Shimada T. Identification and quantitation for complementarity-determining regions of monoclonal antibody by nano-surface and molecular-orientation limited proteolysis, Analyst, 139:576-580(2014).
  71. Harada T, Hamada A, Shimokawa M, Takayama K, Kudoh S, Sato S, Saeki S,  Miyawaki H, Moriyama A, Nakagawa K, Nakanishi Y. Phase I/II tiral of irrinotecan plus amurubicine supported with G-CSF for extended small cell lung cancer, Jpn J Clin Oncol, 44:127-133(2014).
  72. Shimma S, Takashima Y, Hashimoto J, Yonemori K, Tamura K, Hamada A. Alternative two-step matrix application method for imaging mass spectrometry to avoid tissue shrinkage and improve ionization efficiency. J Mass Spectrom, 48:1285-1290 (2013).
  73. Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochem Biophys Res Commun. 439:221-227(2013).
  74. Tsubata Y, Okimoto T, Miura K, Karino F, Iwamoto S, Suzuki T, Hamaguchi S, Kanda H. Sutani A, Kuraki T, Hamada A, Isobe T. Phase I clinical and pharmacokinetics study of bi-weekly carboplatin/paclitaxel chemotherapy in aged patients with non-small-cell lung cancer, Anticancer Research, 33:261-266(2013).
  75. Tsubata Y, Hamada A, Sutani A, and Isobe T. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient, Journal of Cancer Research and Therapeutics, 8: 154-156(2012).
  76. Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, Ushijima S, Urata M, Kishi H, Fujii S, Semba H, Kashiwabara K, Tsubata Y, Kai Y, Isobe T, Kourogi H, Saito H. Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer, Pharmacogenomics, 13:615-624(2012).


<政策提言>

医薬品開発における質量分析イメージング技術利用に関するリフレクションペーパー(2016年度)